Lanner Helps AstraZeneca Gear up for a World Bestseller

Astrazeneca.pdf

AstraZeneca, one of the top five pharmaceutical companies in the world with sales of over £11 billion, is bringing several new drugs to market over the next few years. The ability to bring these to market quickly and to meet expected demand from day one will be critical to the future profitability of the company. One of the new products is an important class-leading drug in its field. It is anticipated that it will be an international bestseller and the company is gearing up for launch in 2002. The performance of the drug’s supply chain is critical to enabling AstraZeneca to achieve its launch targets and satisfy long-term demand for the new drug. Bulk manufacture of the drug is a multi-stage process carried out at brand new state-of-the-art manufacturing facilities. Lanner Group was commissioned by AstraZeneca to undertake a detailed analysis of the manufacturing site to underpin supply chain performance.